

2024 CPT[®] Updates



AAPC

CPT[®] Disclaimer



- CPT[®] copyright 2023 American Medical Association. All rights reserved.
- Fee schedules, relative value units, conversion factors and/or, related components are not assigned by the AMA, are not part of CPT[®] and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
- CPT[®] is a registered trademark of the American Medical Association.

Objectives



- Overview of the new, revised, and deleted CPT[®] codes for 2024
- Review documentation requirements for the new codes

Code Changes — Now What?



- Review 2024 CPT[®] code changes.
- Order 2024 code books.
- Review all changes to guidelines, notes, and instructions in your book.
- Highlight changes in the book's index pertinent to your specialty and review those changes.

Code Changes — Now What?



- Highlight changes in the tabular section pertinent to your specialty.
- Create a “cheat sheet” of 2024 updates that must be documented differently to capture the needed information, and distribute it to clinicians.
- Review and update superbills, chargemasters, etc.

Code Changes — Now What?



- Upload software changes.
- Train coding and billing staff on changes.
- Check for addenda or errata.
- Communicate with payer/provider reps regarding reimbursement and coverage issues.
- Archive last year's books.

Unchanged for 2024



- Appendices
 - There are no changes to the CPT[®] appendices for 2024.
- Anesthesia codes
- CPT[®] modifiers – no modifier changes for 2024.

Evaluation and Management



- ★ ▲ 99202 **Office or other outpatient visit** for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and straightforward medical decision making.

When using total time on the date of the encounter for code selection, ~~15-29 minutes of total time is spent on the date of the encounter~~ minutes must be met or exceeded.

Evaluation and Management



- ★ ▲ 99203 **Office or other outpatient visit** for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and low level of medical decision making.

When using total time on the date of the encounter for code selection, 30-44 ~~minutes of total time is spent on the date of the encounter~~ minutes must be met or exceeded.

Evaluation and Management



★ ▲ 99204 **Office or other outpatient visit** for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and moderate level of medical decision making.

When using total time on the date of the encounter for code selection, ~~45-59~~ minutes of total time is spent on the date of the encounter minutes must be met or exceeded.

Evaluation and Management



★ ▲ 99205 **Office or other outpatient visit** for the evaluation and management of a new patient, which requires a medically appropriate history and/or examination and high level of medical decision making.

When using total time on the date of the encounter for code selection, 60-74 ~~minutes of total time is spent on the date of the encounter~~ minutes must be met or exceeded.

Evaluation and Management



★ ▲ 99212 **Office or other outpatient visit** for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and straightforward medical decision making.

When using total time on the date of the encounter for code selection, 10-19 ~~minutes of total time is spent on the date of the encounter~~ minutes must be met or exceeded.

Evaluation and Management



★ ▲ 99213 **Office or other outpatient visit** for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and low level of medical decision making.

When using total time on the date of the encounter for code selection, ~~20-29~~ minutes of total time is spent on the date of the encounter minutes must be met or exceeded.

Evaluation and Management



★ ▲ 99214 **Office or other outpatient visit** for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and moderate level of medical decision making.

When using total time on the date of the encounter for code selection, ~~30-39~~ minutes of total time is spent on the date of the encounter minutes must be met or exceeded.

Evaluation and Management



★ ▲ 99215 **Office or other outpatient visit** for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and high level of medical decision making.

When using total time on the date of the encounter for code selection, 40-54 ~~minutes of total time is spent on the date of the encounter~~ minutes must be met or exceeded.

Evaluation and Management



▲ 99306 Initial nursing facility care, per day, for the evaluation and management of a patient, which requires a medically appropriate history and/or examination and high level of medical decision making.

When using total time on the date of the encounter for code selection, 4550 minutes must be met or exceeded.

Evaluation and Management



★ ▲ 99308 Subsequent nursing facility care, per day, for the evaluation and management of a patient, which requires a medically appropriate history and/or examination and low level of medical decision making.

When using total time on the date of the encounter for code selection, ~~15~~20 minutes must be met or exceeded.

Surgery



- Revision of intermediate and complex repairs
- Intermediate
 - Limited undermining
- Complex: one of the following
 - Exposure of bone, cartilage, tendon, or named neurovascular structure
 - Debridement of wound edges
 - Extensive undermining
 - Involvement of free margins of helical rim, vermilion border, or nostril rim
 - Placement of retention sutures

Surgery



- #●22836 Anterior thoracic vertebral body tethering, including thoracoscopy, when performed; up to 7 vertebral segments
- #●22837 Anterior thoracic vertebral body tethering, including thoracoscopy, when performed; 8 or more vertebral segments
- #●22838 Revision (eg, augmentation, division of tether), replacement, or removal of thoracic vertebral body tethering, including thoracoscopy, when performed
- #●27278 Arthrodesis, sacroiliac joint, percutaneous, with image guidance, including placement of intra-articular implant(s) (eg, bone allograft[s], synthetic device[s]), without placement of transfixation device
- ▲ 28292 Correction, hallux valgus with {bunionectomy}, with sesamoidectomy, when performed; with resection of proximal phalanx base, when performed, any method

Surgery



- ▲ **28296** Correction, hallux valgus with {bunionectomy}, with sesamoidectomy, when performed; with distal metatarsal osteotomy, any method
- # ▲ **28295** Correction, hallux valgus with {bunionectomy}, with sesamoidectomy, when performed; with proximal metatarsal osteotomy, any method
- ▲ **28297** Correction, hallux valgus with {bunionectomy}, with sesamoidectomy, when performed; with first metatarsal and medial cuneiform joint arthrodesis, any method
- ▲ **28298** Correction, hallux valgus with {bunionectomy}, with sesamoidectomy, when performed; with proximal phalanx osteotomy, any method
- ▲ **28299** Correction, hallux valgus with {bunionectomy}, with sesamoidectomy, when performed; with double osteotomy, any method

Surgery



- #●31242 Nasal/sinus endoscopy, surgical; with destruction by radiofrequency ablation, posterior nasal nerve
- #●31243 Nasal/sinus endoscopy, surgical; with destruction by cryoablation, posterior nasal nerve
- #●33276 Insertion of phrenic nerve stimulator system (pulse generator and stimulating lead[s]), including vessel catheterization, all imaging guidance, and pulse generator initial analysis with diagnostic mode activation, when performed
- #+●33277 Insertion of phrenic nerve stimulator transvenous sensing lead (List separately in addition to code for primary procedure)
- #●33278 Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; system, including pulse generator and lead(s)

Surgery



- #●**33279** Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s) only
- #●**33280** Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only
- #●**33281** Repositioning of phrenic nerve stimulator transvenous lead(s)
- #●**33287** Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator
- #●**33288** Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s)

Surgery



- **52284** Cystourethroscopy, with mechanical urethral dilation and urethral therapeutic drug delivery by drug-coated balloon catheter for urethral stricture or stenosis, male, including fluoroscopy, when performed
- **58580** Transcervical ablation of uterine fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency
- **61889** Insertion of skull-mounted cranial neurostimulator pulse generator or receiver, including craniectomy or craniotomy, when performed, with direct or inductive coupling, with connection to depth and/or cortical strip electrode array(s)
- **61891** Revision or replacement of skull-mounted cranial neurostimulator pulse generator or receiver with connection to depth and/or cortical strip electrode array(s)
- **61892** Removal of skull-mounted cranial neurostimulator pulse generator or receiver with cranioplasty, when performed

Surgery



- ▲ **63685** Insertion or replacement of spinal neurostimulator pulse generator or receiver, ~~direct or inductive coupling~~, requiring pocket creation and connection between electrode array and pulse generator or receiver
- ▲ **63688** Revision or removal of implanted spinal neurostimulator pulse generator or receiver, with detachable connection to electrode array
- ▲ **64590** Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, ~~direct or inductive coupling~~ requiring pocket creation and connection between electrode array and pulse generator or receiver
- ▲ **64595** Revision or removal of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, with detachable connection to electrode array

Surgery



- **64596** Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array
- **64597** Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; each additional electrode array (List separately in addition to code for primary procedure)
- **64598** Revision or removal of neurostimulator electrode array, peripheral nerve, with integrated neurostimulator
- **67516** Suprachoroidal space injection of pharmacologic agent (separate procedure)

Radiology



- 74710** ~~Pelvimetry, with or without placental localization~~
- **75580** Noninvasive estimate of coronary fractional flow reserve (FFR) derived from augmentative software analysis of the data set from a coronary computed tomography angiography, with interpretation and report by a physician or other qualified health care professional
- **76984** Ultrasound, intraoperative thoracic aorta (eg, epiaortic), diagnostic
- **76987** Intraoperative epicardial cardiac ultrasound (ie, echocardiography) for congenital heart disease, diagnostic; including placement and manipulation of transducer, image acquisition, interpretation and report
- **76988** Intraoperative epicardial cardiac ultrasound (ie, echocardiography) for congenital heart disease, diagnostic; placement, manipulation of transducer, and image acquisition only
- **76989** Intraoperative epicardial cardiac ultrasound (ie, echocardiography) for congenital heart disease, diagnostic; interpretation and report only

Radiology



- ▲ **77402** Radiation treatment delivery, $\neq \geq 1$ MeV; simple
- ▲ **77407** Radiation treatment delivery, $\neq \geq 1$ MeV; intermediate
- ▲ **77412** Radiation treatment delivery, $\neq \geq 1$ MeV; complex

Pathology and Laboratory



- ▲ **81171** *AFF2 (AF4/FMR2 family, member 2) transcription elongation factor 2 [FMR2]* (eg, fragile X ~~mental retardation~~ intellectual disability 2 [FRAXE]) gene analysis; evaluation to detect abnormal (eg, expanded) alleles
- ▲ **81172** *AFF2 (AF4/FMR2 family, member 2) transcription elongation factor 2 [FMR2]* (eg, fragile X ~~mental retardation~~ intellectual disability 2 [FRAXE]) gene analysis; characterization of alleles (eg, expanded size and methylation status)
- ▲ **81243** *FMR1 (fragile X ~~mental retardation~~ messenger ribonucleoprotein 1)* (eg, fragile X ~~mental retardation~~ syndrome, X-linked intellectual disability XLID) gene analysis; evaluation to detect abnormal (eg, expanded) alleles
- ▲ **81244** *FMR1 (fragile X ~~mental retardation~~ messenger ribonucleoprotein 1)* (eg, fragile X ~~mental retardation~~ syndrome, X-linked intellectual disability XLID) gene analysis; characterization of alleles (eg, expanded size and promoter methylation status)

Pathology and Laboratory



- ▲ **81403** Molecular pathology procedure, Level 4 (eg, analysis of single exon by DNA sequence analysis, analysis of >10 amplicons using multiplex PCR in 2 or more independent reactions, mutation scanning or duplication/deletion variants of 2-5 exons)
ARX (aristaless -related homeobox) (eg, X-linked lissencephaly with ambiguous genitalia, X-linked ~~mental retardation~~ intellectual disability), duplication/deletion analysis

- ▲ **81404** Molecular pathology procedure, Level 5 (eg, analysis of 2-5 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 6-10 exons, or characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis)
ARX (aristaless related homeobox) (eg, X-linked lissencephaly with ambiguous genitalia, X-linked ~~mental retardation~~ intellectual disability), full gene sequence
ZNF41 (zinc finger protein 41) (eg, X-linked ~~mental retardation~~ intellectual disability 89), full gene sequence

Pathology and Laboratory



- ▲ **81405** Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons, regionally targeted cytogenomic array analysis)
FTSJ1 (FtsJ RNA methyltransferase homolog 1 [E. coli] 2'-O-methyltransferase 1) (eg, X-linked ~~mental retardation~~ intellectual disability 9), duplication/deletion analysis
- ▲ **81406** Molecular pathology procedure, Level 7 (eg, analysis of 11-25 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 26-50 exons)
FTSJ1 (FtsJ RNA 2'-O-methyltransferase 1 methyltransferase homolog 1 [E. coli]) (eg, X-linked ~~mental retardation~~ intellectual disability 9), full gene sequence
- ▲ **81407** Molecular pathology procedure, Level 8 (eg, analysis of 26-50 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of >50 exons, sequence analysis of multiple genes on one platform)
KDM5C (lysine [K]-specific demethylase 5C) (eg, X-linked ~~mental retardation~~ intellectual disability), full gene sequence

Pathology and Laboratory



- ▲ **81445** ~~Targeted genomic sequence analysis panel, s~~Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, MET, NRAS, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed; DNA analysis or combined DNA and RNA analysis
- ▲ **81449** ~~Targeted genomic sequence analysis panel, s~~Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes (eg, ALK, BRAF, CDKN2A, EGFR, ERBB2, KIT, KRAS, MET, NRAS, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, if performed; DNA analysis or combined DNA and RNA analysis
- ▲ **81450** ~~Targeted genomic sequence analysis panel, h~~Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes (eg, BRAF, CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NOTCH1, NPM1, NRAS), interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; DNA analysis or combined DNA and RNA analysis

Pathology and Laboratory



- ▲ **81451** ~~Targeted genomic sequence analysis panel, h~~Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes (eg, ~~*BRAF, CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MLL, NOTCH1, NPM1, NRAS*~~), interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis

- ▲ **81455** ~~Targeted genomic sequence analysis panel, s~~Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, (eg, ~~*ALK, BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MET, MLL, NOTCH1, NPM1, NRAS, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET*~~), interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; DNA analysis or combined DNA and RNA analysis

Pathology and Laboratory



- ▲ **81456** ~~Targeted genomic sequence analysis panel, s~~Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, (eg, ALK, BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MET, MLL, NOTCH1, NPM1, NRAS, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis
- **81457** Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis, microsatellite instability
- **81458** Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis, copy number variants and microsatellite instability
- **81459** Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements

Pathology and Laboratory



- #● **81462** Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants and rearrangements
- #● **81463** Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis, copy number variants, and microsatellite instability
- #● **81464** Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (eg, plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements
- **81517** Liver disease, analysis of 3 biomarkers (hyaluronic acid [HA], procollagen III amino terminal peptide [PIIINP], tissue inhibitor of metalloproteinase 1 [TIMP-1]), using immunoassays, utilizing serum, prognostic algorithm reported as a risk score and risk of liver fibrosis and liver-related clinical events within 5 years

Pathology and Laboratory



- **82166** Anti-mullerian hormone (AMH)
- #● **86041** Acetylcholine receptor (AChR); binding antibody
- #● **86042** Acetylcholine receptor (AChR); blocking antibody
- #● **86043** Acetylcholine receptor (AChR); modulating antibody
- #● **86366** Muscle-specific kinase (MuSK) antibody
- ▲ **87467** Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; hepatitis B surface antigen (HBsAg), quantitative
- **87523** Infectious agent detection by nucleic acid (DNA or RNA); hepatitis D (delta), quantification, including reverse transcription, when performed
- **87593** Infectious agent detection by nucleic acid (DNA or RNA); Orthopoxvirus (eg, monkeypox virus, cowpox virus, vaccinia virus), amplified probe technique, each

Pathology and Laboratory



- ▲ **0022U** Targeted genomic sequence analysis panel, ~~cholangiocarcinoma and non-small cell lung neoplasia~~, DNA and RNA analysis, ~~1–23 genes~~, interrogation for sequence variants and rearrangements, reported as presence ~~/or~~ absence of variants and associated therapy(ies) to consider

- 0053U** ~~Oncology (prostate cancer), FISH analysis of 4 genes (ASAP1, HDAC9, CHD1 and PTEN), needle biopsy specimen, algorithm reported as probability of higher tumor grade~~

- 0066U** ~~Placental alpha-micro-globulin-1 (PAMG-1), immunoassay with direct optical observation, cervico-vaginal fluid, each specimen~~

- ▲ **0095U** ~~Inflammation (eEosinophilic esophagitis), ELISA analysis of e(Eotaxin-3 {[CCL26 {[C-C motif chemokine ligand 26]}]} and major basic protein {[PRG2 {[proteoglycan 2, pro eosinophil major basic protein]}]}), enzyme-linked immunosorbent assays (ELISA), specimen obtained by ~~swallowed nylon-esophageal string test device~~, algorithm reported as ~~predictive probability index for~~ of active or inactive eosinophilic esophagitis~~

Pathology and Laboratory



- 0143U** ~~Drug assay, definitive, 120 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service~~
- 0144U** ~~Drug assay, definitive, 160 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service~~
- 0145U** ~~Drug assay, definitive, 65 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service~~
- 0146U** ~~Drug assay, definitive, 80 or more drugs or metabolites, urine, by quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service~~

Pathology and Laboratory



- 0147U** ~~Drug assay, definitive, 85 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service~~
- 0148U** ~~Drug assay, definitive, 100 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service~~
- 0149U** ~~Drug assay, definitive, 60 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service~~
- 0150U** ~~Drug assay, definitive, 120 or more drugs or metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, comments including sample validation, per date of service~~

Pathology and Laboratory



- ▲ **0269U** Hematology (autosomal dominant congenital thrombocytopenia), genomic sequence analysis of 4422 genes, blood, buccal swab, or amniotic fluid
- ▲ **0271U** Hematology (congenital neutropenia), genomic sequence analysis of 2324 genes, blood, buccal swab, or amniotic fluid
- ▲ **0272U** Hematology (genetic bleeding disorders), genomic sequence analysis of 5160 genes and duplication/ deletion of *PLAU*, blood, buccal swab, or amniotic fluid, comprehensive
- ▲ **0274U** Hematology (genetic platelet disorders), genomic sequence analysis of 4362 genes and duplication/ deletion of *PLAU*, blood, buccal swab, or amniotic fluid
- ▲ **0277U** Hematology (genetic platelet function disorder), genomic sequence analysis of 3140 genes and duplication/ deletion of *PLAU*, blood, buccal swab, or amniotic fluid
- ▲ **0278U** Hematology (genetic thrombosis), genomic sequence analysis of 4214 genes, blood, buccal swab, or amniotic fluid
- ▲ **0308U** Cardiology (coronary artery disease [CAD]), analysis of 3 proteins (high sensitivity [hs] troponin, adiponectin, and kidney injury molecule-1 [KIM-1]) with 3 clinical parameters (age, sex, history of cardiac intervention), plasma, algorithm reported as a risk score for obstructive CAD

Pathology and Laboratory



- 0324U** ~~Oncology (ovarian), spheroid cell culture, 4-drug panel (carboplatin, doxorubicin, gemcitabine, paclitaxel), tumor chemotherapy response prediction for each drug~~
- 0325U** ~~Oncology (ovarian), spheroid cell culture, poly (ADP-ribose) polymerase (PARP) inhibitors (niraparib, olaparib, rucaparib, velparib), tumor response prediction for each drug~~
- ▲ 0351U** Infectious disease (bacterial or viral), biochemical assays, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein-10 (IP-10), and C-reactive protein, serum, or venous whole blood, algorithm reported as likelihood of bacterial infection
- 0355U** APOL1 (apolipoprotein L1) (eg, chronic kidney disease), risk variants (G1, G2)
- ▲ 0356U** Oncology (oropharyngeal or anal), evaluation of 17 DNA biomarkers using droplet digital PCR (ddPCR), cell-free DNA, algorithm reported as a prognostic risk score for cancer recurrence
- 0357U** ~~Oncology (melanoma), artificial intelligence (AI)-enabled quantitative mass spectrometry analysis of 142 unique pairs of glycopeptide and product fragments, plasma, prognostic, and predictive algorithm reported as likely, unlikely, or uncertain benefit from immunotherapy agents~~

Pathology and Laboratory



- **0358U** Neurology (mild cognitive impairment), analysis of β -amyloid 1-42 and 1-40, chemiluminescence enzyme immunoassay, cerebral spinal fluid, reported as positive, likely positive, or negative
- **0359U** Oncology (prostate cancer), analysis of all prostate-specific antigen (PSA) structural isoforms by phase separation and immunoassay, plasma, algorithm reports risk of cancer
- **0360U** Oncology (lung), enzyme-linked immunosorbent assay (ELISA) of 7 autoantibodies (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, MAGE A4, and HuD), plasma, algorithm reported as a categorical result for risk of malignancy
- **0361U** Neurofilament light chain, digital immunoassay, plasma, quantitative
- ▲ **0362U** Oncology (papillary thyroid cancer), gene-expression profiling via targeted hybrid capture–enrichment RNA sequencing of 82 content genes and 10 housekeeping genes, fine needle aspirate or formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as one of three molecular subtypes

Pathology and Laboratory



- **0363U** Oncology (urothelial), mRNA, gene-expression profiling by real-time quantitative PCR of 5 genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm incorporates age, sex, smoking history, and macrohematuria frequency, reported as a risk score for having urothelial carcinoma
- **0364U** Oncology (hematolymphoid neoplasm), genomic sequence analysis using multiplex (PCR) and next-generation sequencing with algorithm, quantification of dominant clonal sequence(s), reported as presence or absence of minimal residual disease (MRD) with quantitation of disease burden, when appropriate
- **0365U** Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGFA) by immunoassays, urine, algorithm reported as a probability of bladder cancer
- **0366U** Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGFA) by immunoassays, urine, algorithm reported as a probability of recurrent bladder cancer

Pathology and Laboratory



- **0367U** Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGFA) by immunoassays, urine, diagnostic algorithm reported as a risk score for probability of rapid recurrence of recurrent or persistent cancer following transurethral resection
- **0368U** Oncology (colorectal cancer), evaluation for mutations of APC, BRAF, CTNNB1, KRAS, NRAS, PIK3CA, SMAD4, and TP53, and methylation markers (MYO1G, KCNQ5, C9ORF50, FLI1, CLIP4, ZNF132, and TWIST1), multiplex quantitative polymerase chain reaction (qPCR), circulating cell-free DNA (cfDNA), plasma, report of risk score for advanced adenoma or colorectal cancer
- **0369U** Infectious agent detection by nucleic acid (DNA and RNA), gastrointestinal pathogens, 31 bacterial, viral, and parasitic organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique
- **0370U** Infectious agent detection by nucleic acid (DNA and RNA), surgical wound pathogens, 34 microorganisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, wound swab

Pathology and Laboratory



- **0371U** Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogen, semiquantitative identification, DNA from 16 bacterial organisms and 1 fungal organism, multiplex amplified probe technique via quantitative polymerase chain reaction (qPCR), urine
- **0372U** Infectious disease (genitourinary pathogens), antibiotic-resistance gene detection, multiplex amplified probe technique, urine, reported as an antimicrobial stewardship risk score
- **0373U** Infectious agent detection by nucleic acid (DNA and RNA), respiratory tract infection, 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes, multiplex amplified probe technique, upper or lower respiratory specimen
- **0374U** Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 21 bacterial and fungal organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, urine

Pathology and Laboratory



- **0375U** Oncology (ovarian), biochemical assays of 7 proteins (follicle stimulating hormone, human epididymis protein 4, apolipoprotein A-1, transferrin, beta-2 macroglobulin, prealbumin [ie, transthyretin], and cancer antigen 125), algorithm reported as ovarian cancer risk score
- **0376U** Oncology (prostate cancer), image analysis of at least 128 histologic features and clinical factors, prognostic algorithm determining the risk of distant metastases, and prostate cancer-specific mortality, includes predictive algorithm to androgen deprivation-therapy response, if appropriate
- **0377U** Cardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by nuclear magnetic resonance (NMR) spectrometry with report of a lipoprotein profile (including 23 variables)
- **0378U** RFC1 (replication factor C subunit 1), repeat expansion variant analysis by traditional and repeat-primed PCR, blood, saliva, or buccal swab

Pathology and Laboratory



- **0379U** Targeted genomic sequence analysis panel, solid organ neoplasm, DNA (523 genes) and RNA (55 genes) by next-generation sequencing, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutational burden
- **0380U** Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis, 20 gene variants and CYP2D6 deletion or duplication analysis with reported genotype and phenotype
- **0381U** Maple syrup urine disease monitoring by patient-collected blood card sample, quantitative measurement of allo-isoleucine, leucine, isoleucine, and valine, liquid chromatography with tandem mass spectrometry (LC-MS/MS)
- **0382U** Hyperphenylalaninemia monitoring by patient-collected blood card sample, quantitative measurement of phenylalanine and tyrosine, liquid chromatography with tandem mass spectrometry (LC-MS/MS)

Pathology and Laboratory



- **0383U** Tyrosinemia type I monitoring by patient-collected blood card sample, quantitative measurement of tyrosine, phenylalanine, methionine, succinylacetone, nitisinone, liquid chromatography with tandem mass spectrometry (LC-MS/MS)
- **0384U** Nephrology (chronic kidney disease), carboxymethyllysine, methylglyoxal hydroimidazolone, and carboxyethyl lysine by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and HbA1c and estimated glomerular filtration rate (GFR), with risk score reported for predictive progression to high-stage kidney disease
- **0385U** Nephrology (chronic kidney disease), apolipoprotein A4 (ApoA4), CD5 antigen-like (CD5L), and insulin-like growth factor binding protein 3 (IGFBP3) by enzyme-linked immunoassay (ELISA), plasma, algorithm combining results with HDL, estimated glomerular filtration rate (GFR) and clinical data reported as a risk score for developing diabetic kidney disease
- ~~**0386U** Gastroenterology (Barrett's esophagus), P16, RUNX3, HPP1, and FBN1 methylation analysis, prognostic and predictive algorithm reported as a risk score for progression to high-grade dysplasia or esophageal cancer~~



- **0387U** Oncology (melanoma), autophagy and beclin 1 regulator 1 (AMBRA1) and loricrin (AMLo) by immunohistochemistry, formalin-fixed paraffin-embedded (FFPE) tissue, report for risk of progression
- **0388U** Oncology (non-small cell lung cancer), next-generation sequencing with identification of single nucleotide variants, copy number variants, insertions and deletions, and structural variants in 37 cancer-related genes, plasma, with report for alteration detection
- **0389U** Pediatric febrile illness (Kawasaki disease [KD]), interferon alpha-inducible protein 27 (IFI27) and mast cell-expressed membrane protein 1 (MCEMP1), RNA, using quantitative reverse transcription polymerase chain reaction (RT-qPCR), blood, reported as a risk score for KD
- **0390U** Obstetrics (preeclampsia), kinase insert domain receptor (KDR), Endoglin (ENG), and retinol-binding protein 4 (RBP4), by immunoassay, serum, algorithm reported as a risk score

Pathology and Laboratory



- **0391U** Oncology (solid tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded (FFPE) tissue, 437 genes, interpretive report for single nucleotide variants, splice-site variants, insertions/deletions, copy number alterations, gene fusions, tumor mutational burden, and microsatellite instability, with algorithm quantifying immunotherapy response score
- **0392U** Drug metabolism (depression, anxiety, attention deficit hyperactivity disorder [ADHD]), gene-drug interactions, variant analysis of 16 genes, including deletion/duplication analysis of CYP2D6, reported as impact of gene-drug interaction for each drug
- **0393U** Neurology (eg, Parkinson disease, dementia with Lewy bodies), cerebrospinal fluid (CSF), detection of misfolded α -synuclein protein by seed amplification assay, qualitative
- **0394U** Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 16 PFAS compounds by liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma or serum, quantitative

Pathology and Laboratory



- **0395U** Oncology (lung), multi-omics (microbial DNA by shotgun next-generation sequencing and carcinoembryonic antigen and osteopontin by immunoassay), plasma, algorithm reported as malignancy risk for lung nodules in early-stage disease
- **0396U** Obstetrics (pre-implantation genetic testing), evaluation of 300000 DNA single-nucleotide polymorphisms (SNPs) by microarray, embryonic tissue, algorithm reported as a probability for single-gene germline conditions
- **0397U** ~~Oncology (non-small cell lung cancer), cell-free DNA from plasma, targeted sequence analysis of at least 109 genes, including sequence variants, substitutions, insertions, deletions, select rearrangements, and copy number variations~~
- **0398U** Gastroenterology (Barrett's esophagus), P16, RUNX3, HPP1, and FBN1 DNA methylation analysis using PCR, formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as risk score for progression to high-grade dysplasia or cancer
- **0399U** Neurology (cerebral folate deficiency), serum, detection of anti-human folate receptor IgG-binding antibody and blocking autoantibodies by enzyme-linked immunoassay (ELISA), qualitative, and blocking autoantibodies, using a functional blocking assay for IgG or IgM, quantitative, reported as positive or not detected

Pathology and Laboratory



- **0400U** Obstetrics (expanded carrier screening), 145 genes by next-generation sequencing, fragment analysis and multiplex ligation-dependent probe amplification, DNA, reported as carrier positive or negative
- **0401U** Cardiology (coronary heart disease [CHD]), 9 genes (12 variants), targeted variant genotyping, blood, saliva, or buccal swab, algorithm reported as a genetic risk score for a coronary event
- **0402U** Infectious agent (sexually transmitted infection), Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, multiplex amplified probe technique, vaginal, endocervical, or male urine, each pathogen reported as detected or not detected
- **0403U** Oncology (prostate), mRNA, gene expression profiling of 18 genes, first-catch post-digital rectal examination urine (or processed first-catch urine), algorithm reported as percentage of likelihood of detecting clinically significant prostate cancer
- **0404U** Oncology (breast), semiquantitative measurement of thymidine kinase activity by immunoassay, serum, results reported as risk of disease progression

Pathology and Laboratory



- **0405U** Oncology (pancreatic), 59 methylation haplotype block markers, next-generation sequencing, plasma, reported as cancer signal detected or not detected
- **0406U** Oncology (lung), flow cytometry, sputum, 5 markers (meso-tetra [4-carboxyphenyl] porphyrin [TCPP], CD206, CD66b, CD3, CD19), algorithm reported as likelihood of lung cancer
- **0407U** Nephrology (diabetic chronic kidney disease [CKD]), multiplex electrochemiluminescent immunoassay (ECLIA) of soluble tumor necrosis factor receptor 1 (sTNFR1), soluble tumor necrosis receptor 2 (sTNFR2), and kidney injury molecule 1 (KIM-1) combined with clinical data, plasma, algorithm reported as risk for progressive decline in kidney function
- **0408U** Infectious agent antigen detection by bulk acoustic wave biosensor immunoassay, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])
- **0409U** Oncology (solid tumor), DNA (80 genes) and RNA (36 genes), by next-generation sequencing from plasma, including single nucleotide variants, insertions/deletions, copy number alterations, microsatellite instability, and fusions, report showing identified mutations with clinical actionability

Pathology and Laboratory



- **0410U** Oncology (pancreatic), DNA, whole genome sequencing with 5-hydroxymethylcytosine enrichment, whole blood or plasma, algorithm reported as cancer detected or not detected
- ✂● **0411U** Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6
- **0412U** Beta amyloid, A β 42/40 ratio, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and qualitative ApoE isoform-specific proteotyping, plasma combined with age, algorithm reported as presence or absence of brain amyloid pathology
- **0413U** Oncology (hematolymphoid neoplasm), optical genome mapping for copy number alterations, aneuploidy, and balanced/complex structural rearrangements, DNA from blood or bone marrow, report of clinically significant alterations
- **0414U** Oncology (lung), augmentative algorithmic analysis of digitized whole slide imaging for 8 genes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1), and KRAS G12C and PD-L1, if performed, formalin-fixed paraffin-embedded (FFPE) tissue, reported as positive or negative for each biomarker

Pathology and Laboratory



- **0415U** Cardiovascular disease (acute coronary syndrome [ACS]), IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, and MCP-3 by immunoassay combined with age, sex, family history, and personal history of diabetes, blood, algorithm reported as a 5-year (deleted risk) score for ACS
- **0416U** Infectious agent detection by nucleic acid (DNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms, including identification of 20 associated antibiotic-resistance genes, if performed, multiplex amplified probe technique, urine
- **0417U** Rare diseases (constitutional/heritable disorders), whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, nuclear-encoded mitochondrial gene analysis of 335 nuclear genes, including sequence changes, deletions, insertions, and copy number variants analysis, blood or saliva, identification and categorization of mitochondrial disorder-associated genetic variants
- **0418U** Oncology (breast), augmentative algorithmic analysis of digitized whole slide imaging of 8 histologic and immunohistochemical features, reported as a recurrence score
- **0419U** Neuropsychiatry (eg, depression, anxiety), genomic sequence analysis panel, variant analysis of 13 genes, saliva or buccal swab, report of each gene phenotype

Pathology and Laboratory



- **0420U** Oncology (urothelial), mRNA expression profiling by real-time quantitative PCR of MDK, HOXA13, CDC2, IGFBP5, and CXCR2 in combination with droplet digital PCR (ddPCR) analysis of 6 single-nucleotide polymorphisms (SNPs) genes TERT and FGFR3, urine, algorithm reported as a risk score for urothelial carcinoma
- **0421U** Oncology (colorectal) screening, quantitative real-time target and signal amplification of 8 RNA markers (GAPDH, SMAD4, ACY1, AREG, CDH1, KRAS, TNFRSF10B, EGLN2) and fecal hemoglobin, algorithm reported as a positive or negative for colorectal cancer risk
- **0422U** Oncology (pan-solid tumor), analysis of DNA biomarker response to anti-cancer therapy using cell-free circulating DNA, biomarker comparison to a previous baseline pre-treatment cell-free circulating DNA analysis using next-generation sequencing, algorithm reported as a quantitative change from baseline, including specific alterations, if appropriate
- **0423U** Psychiatry (eg, depression, anxiety), genomic analysis panel, including variant analysis of 26 genes, buccal swab, report including metabolizer status and risk of drug toxicity by condition

Pathology and Laboratory



- **0424U** Oncology (prostate), exosome-based analysis of 53 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT-qPCR), urine, reported as no molecular evidence, low-, moderate- or elevated-risk of prostate cancer
- **0425U** Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis, each comparator genome (eg, parents, siblings)
- **0426U** Genome (eg, unexplained constitutional or heritable disorder or syndrome), ultra-rapid sequence analysis
- + ● **0427U** Monocyte distribution width, whole blood (List separately in addition to code for primary procedure)
- **0428U** Oncology (breast), targeted hybrid-capture genomic sequence analysis panel, circulating tumor DNA (ctDNA) analysis of 56 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutation burden

Pathology and Laboratory



- **0429U** Human papillomavirus (HPV), oropharyngeal swab, 14 high-risk types (ie, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68)
- **0430U** Gastroenterology, malabsorption evaluation of alpha-1-antitrypsin, calprotectin, pancreatic elastase and reducing substances, feces, quantitative
- **0431U** Glycine receptor alpha1 IgG, serum or cerebrospinal fluid (CSF), live cell-binding assay (LCBA), qualitative
- **0432U** Kelch-like protein 11 (KLHL11) antibody, serum or cerebrospinal fluid (CSF), cell-binding assay, qualitative
- **0433U** Oncology (prostate), 5 DNA regulatory markers by quantitative PCR, whole blood, algorithm, including prostate-specific antigen, reported as likelihood of cancer

Pathology and Laboratory



- **0434U** Drug metabolism (adverse drug reactions and drug response), genomic analysis panel, variant analysis of 25 genes with reported phenotypes
- **0435U** Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on cytotoxicity percentage observed, minimum of 14 drugs or drug combinations
- **0436U** Oncology (lung), plasma analysis of 388 proteins, using aptamer-based proteomics technology, predictive algorithm reported as clinical benefit from immune checkpoint inhibitor therapy
- **0437U** Psychiatry (anxiety disorders), mRNA, gene expression profiling by RNA sequencing of 15 biomarkers, whole blood, algorithm reported as predictive risk score
- **0438U** Drug metabolism (adverse drug reactions and drug response), buccal specimen, gene-drug interactions, variant analysis of 33 genes, including deletion/duplication analysis of CYP2D6, including reported phenotypes and impacted gene-drug interactions

Medicine



- **90380** Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use
- **90381** Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use
- #● **90480** Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose

Medicine



AMA deleted the following COVID-19-related codes on Nov. 1, 2023. These codes appear in the 2024 CPT® code book because it went to print before these code changes were finalized.

0001A	0034A	0072A	0104A	0151A	91303	91314
0002A	0041A	0073A	0111A	0154A	91305	91315
0003A	0042A	0074A	0112A	0164A	91306	91316
0004A	0044A	0081A	0113A	0171A	91307	91317
0011A	0051A	0082A	0121A	0172A	91308	
0012A	0052A	0083A	0124A	0173A	91309	
0013A	0053A	0091A	0134A	0174A	91310	
0021A	0054A	0092A	0141A	91300	91311	
0022A	0064A	0093A	0142A	91301	91312	
0031A	0071A	0094A	0144A	91302	91313	

Medicine



- #● **91316** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use
- #⚡● **90589** Chikungunya virus vaccine, live attenuated, for intramuscular use
- **90679** Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use
- #⚡● **90683** Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use
- #● **90611** Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, non-replicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous use
- #● **90622** Vaccinia (smallpox) virus vaccine, live, lyophilized, 0.3 mL dosage, for percutaneous use
- #⚡● **90623** Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y- tetanus toxoid carrier, and Men B-FHbp, for intramuscular use
- #▲ **91304** Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [Covid-19]) Vaccine, Recombinant Spike Protein Nanoparticle, Saponin-Based Adjuvant, ~~preservative free~~, 5 Mcg/0.5 Ml Dosage, For Intramuscular Use

Medicine



- #● **91318** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
- #● **91319** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
- #● **91320** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
- #● **91321** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use
- #● **91322** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use

Medicine



- **92622** Diagnostic analysis, programming, and verification of an auditory osseointegrated sound processor, any type; first 60 minutes
- + ● **92623** Diagnostic analysis, programming, and verification of an auditory osseointegrated sound processor, any type; each additional 15 minutes (List separately in addition to code for primary procedure)
- #+ ● **92972** Percutaneous transluminal coronary lithotripsy (List separately in addition to code for primary procedure)
- # ● **93150** Therapy activation of implanted phrenic nerve stimulator system, including all interrogation and programming
- # ● **93151** Interrogation and programming (minimum one parameter) of implanted phrenic nerve stimulator system
- # ● **93152** Interrogation and programming of implanted phrenic nerve stimulator system during polysomnography
- # ● **93153** Interrogation without programming of implanted phrenic nerve stimulator system

Medicine



- #+● 93584** Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation; anomalous or persistent superior vena cava when it exists as a second contralateral superior vena cava, with native drainage to heart (List separately in addition to code for primary procedure)
- #+● 93585** Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation; azygos/hemiazygos venous system (List separately in addition to code for primary procedure)
- #+● 93586** Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation; coronary sinus (List separately in addition to code for primary procedure)
- #+● 93587** Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation; venovenous collaterals originating at or above the heart (eg, from innominate vein) (List separately in addition to code for primary procedure)

Medicine



- #+● **93588** Venography for congenital heart defect(s), including catheter placement, and radiological supervision and interpretation; venovenous collaterals originating below the heart (eg, from the inferior vena cava) (List separately in addition to code for primary procedure)

- #● **96380** Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection, with counseling by physician or other qualified health care professional

- #● **96381** Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection

- ▲ **96446** Chemotherapy administration into the peritoneal cavity via ~~indwelling~~ implanted port or catheter

Medicine



- +● 96547** Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) procedure, including separate incision(s) and closure, when performed; first 60 minutes (List separately in addition to code for primary procedure)

- +● 96548** Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) procedure, including separate incision(s) and closure, when performed; each additional 30 minutes (List separately in addition to code for primary procedure)

- ▲ 96920** Excimer Laser treatment for ~~inflammatory skin disease (psoriasis)~~; total area less than 250 sq cm

- ▲ 96921** Excimer Laser treatment for ~~inflammatory skin disease (psoriasis)~~; 250 sq cm to 500 sq cm

- ▲ 96921** Excimer Laser treatment for ~~inflammatory skin disease (psoriasis)~~; over 500 sq cm

Medicine



- #● **97037** Application of a modality to 1 or more areas; low-level laser therapy (ie, nonthermal and non-ablative) for post-operative pain reduction
- **97550** Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community (eg, activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, swallowing, feeding, problem solving, safety practices) (without the patient present), face to face; initial 30 minutes
- +● **97551** Caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community (eg, activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, swallowing, feeding, problem solving, safety practices) (without the patient present), face to face; each additional 15 minutes (List separately in addition to code for primary service)
- **97552** Group caregiver training in strategies and techniques to facilitate the patient's functional performance in the home or community (eg, activities of daily living [ADLs], instrumental ADLs [iADLs], transfers, mobility, communication, swallowing, feeding, problem solving, safety practices) (without the patient present), face to face with multiple sets of caregivers

Category II Codes



- ▲ **1119F** Initial evaluation for condition (HEP C)_(EPI, DSP)
- ▲ **1121F** Subsequent evaluation for condition (HEP C)_(EPI)
- ▲ **3095F** Central dual-energy X-ray absorptiometry (DXA) results documented (OP)_(IBD)
- ▲ **3096F** Central dual-energy X-ray absorptiometry (DXA) ordered (OP)_(IBD)
- ▲ **3216F** Patient has documented immunity to Hepatitis B (HEP-C)_(IBD)
- ▲ **3372F** AJCC Breast Cancer Stage I: T1mic, T1a or T1b (tumor size $\leq \leq 1$ cm) documented (ONC)
- ▲ **3496F** CD4+ cell count ≥ 500 cells/mm³ (HIV)
- ▲ **3498F** CD4+ cell percentage $\geq 15\%$ (HIV)
- ▲ **4194F** Patient receiving ≥ 10 mg daily prednisone (or equivalent) for longer than 6 months, and improvement or no change in disease activity (RA)

Category III Codes



- ~~0404T~~ Transcervical uterine fibroid(s) ablation with ultrasound guidance, radiofrequency
- ~~0424T~~ Insertion or replacement of neurostimulator system for treatment of central sleep apnea; complete system (transvenous placement of right or left stimulation lead, sensing lead, implantable pulse generator)
- ~~0425T~~ Insertion or replacement of neurostimulator system for treatment of central sleep apnea; sensing lead only
- ~~0426T~~ Insertion or replacement of neurostimulator system for treatment of central sleep apnea; stimulation lead only
- ~~0427T~~ Insertion or replacement of neurostimulator system for treatment of central sleep apnea; pulse generator only
- ~~0428T~~ Removal of neurostimulator system for treatment of central sleep apnea; pulse generator only
- ~~0429T~~ Removal of neurostimulator system for treatment of central sleep apnea; sensing lead only
- ~~0430T~~ Removal of neurostimulator system for treatment of central sleep apnea; stimulation lead only
- ~~0431T~~ Removal and replacement of neurostimulator system for treatment of central sleep apnea, pulse generator only

Category III Codes



- ~~0432T~~ ~~Repositioning of neurostimulator system for treatment of central sleep apnea; stimulation lead only~~
- ~~0433T~~ ~~Repositioning of neurostimulator system for treatment of central sleep apnea; sensing lead only~~
- ~~0434T~~ ~~Interrogation device evaluation implanted neurostimulator pulse generator system for central sleep apnea~~
- ~~0435T~~ ~~Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; single session~~
- ~~0436T~~ ~~Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; during sleep study~~
- ~~0465T~~ ~~Suprachoroidal injection of a pharmacologic agent (does not include supply of medication)~~
- # ▲ **0640T** Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), other than for screening for peripheral arterial disease, [StO₂]; image acquisition, interpretation, and report; image acquisition, interpretation and report, each flap or woundfirst anatomic site

Category III Codes



- 0641T** ~~Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO₂]); image acquisition only, each flap or wound~~
- 0642T** ~~Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO₂]); interpretation and report only, each flap or wound~~
- #+● 0859T** Noncontact near-infrared spectroscopy (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), other than for screening for peripheral arterial disease, image acquisition, interpretation, and report; each additional anatomic site (List separately in addition to code for primary procedure)
- #● 0860T** Noncontact near-infrared spectroscopy (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), for screening for peripheral arterial disease, including provocative maneuvers, image acquisition, interpretation, and report, one or both lower extremities

Category III Codes



0499T ~~Cystourethroscopy, with mechanical dilation and urethral therapeutic drug delivery for urethral stricture or stenosis, including fluoroscopy, when performed~~

0501T ~~Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery disease; data preparation and transmission, analysis of fluid dynamics and simulated maximal coronary hyperemia, generation of estimated FFR model, with anatomical data review in comparison with estimated FFR model to reconcile discordant data, interpretation and report~~

0502T ~~Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery disease; data preparation and transmission~~

Category III Codes



- 0503T** ~~Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery disease; analysis of fluid dynamics and simulated maximal coronary hyperemia, and generation of estimated FFR model~~
- 0504T** ~~Noninvasive estimated coronary fractional flow reserve (FFR) derived from coronary computed tomography angiography data using computation fluid dynamics physiologic simulation software analysis of functional data to assess the severity of coronary artery disease; anatomical data review in comparison with estimated FFR model to reconcile discordant data, interpretation and report~~
- 0508T** ~~Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia~~
- ▲ 0517T** Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; ~~pulse generator~~both component(s) of pulse generator (battery and/or transmitter) only

Category III Codes



- #● **0861T** Removal of pulse generator for wireless cardiac stimulator for left ventricular pacing; both components (battery and transmitter)
- ▲ **0518T** ~~Removal of only pulse generator component(s) (battery and/or transmitter) or wireless cardiac stimulator for left ventricular pacing~~ battery component only
- #● **0862T** Relocation of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; battery component only
- #● **0863T** Relocation of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; transmitter component only
- ▲ **0519T** Removal and replacement of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; ~~pulse generator~~ both component(s) (battery and/or transmitter)

Category III Codes



- ▲ 0520T** Removal and replacement of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; pulse generator battery component(s) only (battery and/or transmitter), including placement of a new electrode
- ~~0533T~~** ~~Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; includes set-up, patient training, configuration of monitor, data upload, analysis and initial report configuration, download review, interpretation and report~~
- ~~0534T~~** ~~Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; set-up, patient training, configuration of monitor~~
- ~~0535T~~** ~~Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; data upload, analysis and initial report configuration~~
- ~~0536T~~** ~~Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; download review, interpretation and report~~

Category III Codes



- ▲ **0587T** Percutaneous implantation or replacement of integrated single device neurostimulation system for bladder dysfunction including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve
- ▲ **0588T** Revision or removal of percutaneously placed integrated single device neurostimulation system for bladder dysfunction including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve
- ▲ **0589T** Electronic analysis with simple programming of implanted integrated neurostimulation system for bladder dysfunction (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 1-3 parameters

Category III Codes



- ▲ **0590T** Electronic analysis with complex programming of implanted integrated neurostimulation system for bladder dysfunction (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 4 or more parameters
- ▲ **0656T** Anterior lumbar or thoracolumbar ~~V~~vertebral body tethering, ~~anterior~~; up to 7 vertebral segments
- ▲ **0657T** Anterior lumbar or thoracolumbar ~~V~~vertebral body tethering, ~~anterior~~; 8 or more vertebral segments
- #● **0790T** Revision (eg, augmentation, division of tether), replacement, or removal of thoracolumbar or lumbar vertebral body tethering, including thoracoscopy, when performed
- ~~**0715T** Percutaneous transluminal coronary lithotripsy (List separately in addition to code for primary procedure)~~

Category III Codes



- #+ ● 0827T** Digitization of glass microscope slides for cytopathology, fluids, washings, or brushings, except cervical or vaginal; smears with interpretation (List separately in addition to code for primary procedure)
- #+ ● 0828T** Digitization of glass microscope slides for cytopathology, fluids, washings, or brushings, except cervical or vaginal; simple filter method with interpretation (List separately in addition to code for primary procedure)
- #+ ● 0829T** Digitization of glass microscope slides for cytopathology, concentration technique, smears, and interpretation (eg, Saccomanno technique) (List separately in addition to code for primary procedure)
- #+ ● 0830T** Digitization of glass microscope slides for cytopathology, selective-cellular enhancement technique with interpretation (eg, liquid-based slide preparation method), except cervical or vaginal (List separately in addition to code for primary procedure)
- #+ ● 0831T** Digitization of glass microscope slides for cytopathology, cervical or vaginal (any reporting system), requiring interpretation by physician (List separately in addition to code for primary procedure)

Category III Codes



- #+ ● 0832T** Digitization of glass microscope slides for cytopathology, smears, any other source; screening and interpretation (List separately in addition to code for primary procedure)
- #+ ● 0833T** Digitization of glass microscope slides for cytopathology, smears, any other source; preparation, screening and interpretation (List separately in addition to code for primary procedure)
- #+ ● 0834T** Digitization of glass microscope slides for cytopathology, smears, any other source; extended study involving over 5 slides and/or multiple stains (List separately in addition to code for primary procedure)
- #+ ● 0835T** Digitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site (List separately in addition to code for primary procedure)
- #+ ● 0836T** Digitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, each separate additional evaluation episode, same site (List separately in addition to code for primary procedure)

Category III Codes



- #+● 0837T** Digitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; interpretation and report (List separately in addition to code for primary procedure)
- #+● 0838T** Digitization of glass microscope slides for consultation and report on referred slides prepared elsewhere (List separately in addition to code for primary procedure)
- #+● 0839T** Digitization of glass microscope slides for consultation and report on referred material requiring preparation of slides (List separately in addition to code for primary procedure)
- #+● 0840T** Digitization of glass microscope slides for consultation, comprehensive, with review of records and specimens, with report on referred material (List separately in addition to code for primary procedure)
- #+● 0841T** Digitization of glass microscope slides for pathology consultation during surgery; first tissue block, with frozen section(s), single specimen (List separately in addition to code for primary procedure)

Category III Codes



- #+● 0842T** Digitization of glass microscope slides for pathology consultation during surgery; each additional tissue block with frozen section(s) (List separately in addition to code for primary procedure)
- #+● 0843T** Digitization of glass microscope slides for pathology consultation during surgery; cytologic examination (eg, touch preparation, squash preparation), initial site (List separately in addition to code for primary procedure)
- #+● 0844T** Digitization of glass microscope slides for pathology consultation during surgery; cytologic examination (eg, touch preparation, squash preparation), each additional site (List separately in addition to code for primary procedure)
- #+● 0845T** Digitization of glass microscope slides for immunofluorescence, per specimen; initial single antibody stain procedure (List separately in addition to code for primary procedure)
- #+● 0846T** Digitization of glass microscope slides for immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure)

Category III Codes



- #+● 0847T** Digitization of glass microscope slides for examination and selection of retrieved archival (ie, previously diagnosed) tissue(s) for molecular analysis (eg, KRAS mutational analysis) (List separately in addition to code for primary procedure)
- #+● 0848T** Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; initial single probe stain procedure (List separately in addition to code for primary procedure)
- #+● 0849T** Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure)
- #+● 0850T** Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; each multiplex probe stain procedure (List separately in addition to code for primary procedure)
- #+● 0851T** Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; initial single probe stain procedure (List separately in addition to code for primary procedure)

Category III Codes



- #+● 0852T** Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure)
- #+● 0853T** Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; each multiplex probe stain procedure (List separately in addition to code for primary procedure)
- #+● 0854T** Digitization of glass microscope slides for blood smear, peripheral, interpretation by physician with written report (List separately in addition to code for primary procedure)
- #+● 0855T** Digitization of glass microscope slides for bone marrow, smear interpretation (List separately in addition to code for primary procedure)
- #+● 0856T** Digitization of glass microscope slides for electron microscopy, diagnostic (List separately in addition to code for primary procedure)

Category III Codes



- ▲ **0766T** Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, ~~initial treatment~~, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; first nerve
- + ▲ **0767T** Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, ~~initial treatment~~, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; each additional nerve (List separately in addition to code for primary procedure)
- ~~**0768T** Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, subsequent treatment, including noninvasive electroneurographic localization (nerve conduction localization), when performed; first nerve~~
- ~~**0769T** Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, subsequent treatment, including noninvasive electroneurographic localization (nerve conduction localization), each additional nerve (List separately in addition to code for primary procedure)~~

Category III Codes



- ~~0775T Arthrodesis, sacroiliac joint, percutaneous, with image guidance, includes placement of intra-articular implant(s) (eg, bone allograft[s], synthetic device[s])~~
- **0784T** Insertion or replacement of percutaneous electrode array, spinal, with integrated neurostimulator, including imaging guidance, when performed
 - **0785T** Revision or removal of neurostimulator electrode array, spinal, with integrated neurostimulator
 - **0786T** Insertion or replacement of percutaneous electrode array, sacral, with integrated neurostimulator, including imaging guidance, when performed
 - **0787T** Revision or removal of neurostimulator electrode array, sacral, with integrated neurostimulator
 - **0788T** Electronic analysis with simple programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, spinal cord or sacral nerve, 1-3 parameters

Category III Codes



- **0789T** Electronic analysis with complex programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, spinal cord or sacral nerve, 4 or more parameters
- ➕ ● **0791T** Motor-cognitive, semi-immersive virtual reality-facilitated gait training, each 15 minutes (List separately in addition to code for primary procedure)
- **0792T** Application of silver diamine fluoride 38%, by a physician or other qualified health care professional
- **0793T** Percutaneous transcatheter thermal ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance

Category III Codes



- **0794T** Patient-specific, assistive, rules-based algorithm for ranking pharmaco-oncologic treatment options based on the patient's tumor-specific cancer marker information obtained from prior molecular pathology, immunohistochemical, or other pathology results which have been previously interpreted and reported separately
- **0795T** Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; complete system (ie, right atrial and right ventricular pacemaker components)
- **0796T** Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right atrial pacemaker component (when an existing right ventricular single leadless pacemaker exists to create a dual-chamber leadless pacemaker system)

Category III Codes



- **0797T** Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system)
- **0798T** Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; complete system (ie, right atrial and right ventricular pacemaker components)
- **0799T** Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; right atrial pacemaker component

Category III Codes



- **0800T** Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system)
- **0801T** Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; dual-chamber system (ie, right atrial and right ventricular pacemaker components)
- **0802T** Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right atrial pacemaker component

Category III Codes



- **0803T** Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system)
- **0804T** Programming device evaluation (in person) with iterative adjustment of implantable device to test the function of device and to select optimal permanent programmed values, with analysis, review, and report, by a physician or other qualified health care professional, leadless pacemaker system in dual cardiac chambers
- **0805T** Transcatheter superior and inferior vena cava prosthetic valve implantation (ie, caval valve implantation [CAVI]); percutaneous femoral vein approach
- **0806T** Transcatheter superior and inferior vena cava prosthetic valve implantation (ie, caval valve implantation [CAVI]); open femoral vein approach

Category III Codes



- **0807T** Pulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with previously acquired computed tomography (CT) images, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report
- **0808T** Pulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with computed tomography (CT) images taken for the purpose of pulmonary tissue ventilation analysis, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report
- ~~**0809T** Arthrodesis, sacroiliac joint, percutaneous or minimally invasive (indirect visualization), with image guidance, placement of transfixing device(s) and intra-articular implant(s) including allograft or synthetic device(s)~~

Category III Codes



- **0810T** Subretinal injection of a pharmacologic agent, including vitrectomy and 1 or more retinotomies
- **0811T** Remote multi-day complex uroflowmetry (eg, calibrated electronic equipment); set-up and patient education on use of equipment
- **0812T** Remote multi-day complex uroflowmetry (eg, calibrated electronic equipment); device supply with automated report generation, up to 10 days
- **0813T** Esophagogastroduodenoscopy, flexible, transoral, with volume adjustment of intragastric bariatric balloon
- **0814T** Percutaneous injection of calcium-based biodegradable osteoconductive material, proximal femur, including imaging guidance, unilateral
- **0815T** Ultrasound-based radiofrequency echographic multi-spectrometry (REMS), bone-density study and fracture-risk assessment, 1 or more sites, hips, pelvis, or spine

Category III Codes



- **0816T** Open insertion or replacement of integrated neurostimulation system for bladder dysfunction including electrode(s) (eg, array or leadless), and pulse generator or receiver, including analysis, programming, and imaging guidance, when performed, posterior tibial nerve; subcutaneous
- **0817T** Open insertion or replacement of integrated neurostimulation system for bladder dysfunction including electrode(s) (eg, array or leadless), and pulse generator or receiver, including analysis, programming, and imaging guidance, when performed, posterior tibial nerve; subfascial
- **0818T** Revision or removal of integrated neurostimulation system for bladder dysfunction, including analysis, programming, and imaging, when performed, posterior tibial nerve; subcutaneous
- **0819T** Revision or removal of integrated neurostimulation system for bladder dysfunction, including analysis, programming, and imaging, when performed, posterior tibial nerve; subfascial
- **0820T** Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; first physician or other qualified health care professional, each hour

Category III Codes



- + ● 0821T** Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; second physician or other qualified health care professional, concurrent with first physician or other qualified health care professional, each hour (List separately in addition to code for primary procedure)
- + ● 0822T** Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; clinical staff under the direction of a physician or other qualified health care professional, concurrent with first physician or other qualified health care professional, each hour (List separately in addition to code for primary procedure)
- 0823T** Transcatheter insertion of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography) and device evaluation (eg, interrogation or programming), when performed

Category III Codes



- **0824T** Transcatheter removal of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography), when performed
- **0825T** Transcatheter removal and replacement of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography) and device evaluation (eg, interrogation or programming), when performed
- **0826T** Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional, leadless pacemaker system in single-cardiac chamber
- ✚ ● **0857T** Opto-acoustic imaging, breast, unilateral, including axilla when performed, real-time with image documentation, augmentative analysis and report (List separately in addition to code for primary procedure)

Category III Codes



- **0858T** Externally applied transcranial magnetic stimulation with concomitant measurement of evoked cortical potentials with automated report
- **0864T** Low-intensity extracorporeal shock wave therapy involving corpus cavernosum, low energy
- **0865T** Quantitative magnetic resonance image (MRI) analysis of the brain with comparison to prior magnetic resonance (MR) study(ies), including lesion identification, characterization, and quantification, with brain volume(s) quantification and/or severity score, when performed, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the brain during the same session
- **0866T** Quantitative magnetic resonance image (MRI) analysis of the brain with comparison to prior magnetic resonance (MR) study(ies), including lesion detection, characterization, and quantification, with brain volume(s) quantification and/or severity score, when performed, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the brain (List separately in addition to code for primary procedure)

Administrative Multianalyte Assays with Algorithmic Analyses (MAAA)



0014M

~~Liver disease, analysis of 3 biomarkers (hyaluronic acid [HA], procollagen III amino terminal peptide [PIIINP], tissue inhibitor of metalloproteinase 1 [TIMP-1]), using immunoassays, utilizing serum, prognostic algorithm reported as a risk score and risk of liver fibrosis and liver-related clinical events within 5 years~~

- **0019M** Cardiovascular disease, plasma, analysis of protein biomarkers by aptamer-based microarray and algorithm reported as 4-year likelihood of coronary event in high-risk populations